Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology Sells its MCRs Programme to Pfizer

Published: Thursday, June 19, 2014
Last Updated: Thursday, June 19, 2014
Bookmark and Share
Small molecules developed in collaboration with Queen Mary University of London.

MRC Technology has announced that it has sold to Pfizer Inc. its melanocortin receptors (MCRs) programme, which includes a set of small molecules.

Targets for these small molecules came to the attention of MRC Technology from Mauro Perretti, Professor of Immunopharmacology at Queen Mary University of London (QMUL), and MRC Technology ran a screening programme in collaboration with QMUL.

MCRs have a wide and varied distribution throughout the body, being found in the central nervous system, periphery and immune cells.

The undisclosed financial consideration received by MRC Technology from this transaction with Pfizer will be shared with QMUL’s William Harvey Research Institute, of which Professor Perretti is Co-Director.

Under MRC Technology’s not-for-profit collaborative model, revenue retained from this transaction will be reinvested to support other collaborative programmes within its drug discovery labs.

“We believe MCRs have significant therapeutic potential and we are delighted to have completed this transaction with Pfizer,” commented Professor Justin Bryans, Director of Drug Discovery at MRC Technology. “This transaction and similar ones will enable MRC Technology to reinvest in its drug discovery programmes focussed on areas of unmet medical need.”

“We are pleased to have acquired novel early-stage compounds discovered by MRC Technology,” said Tim Rolph, Vice President and Chief Scientific Officer of Cardiovascular, Metabolic & Endocrine Disease Research at Pfizer Inc. “Through research and development efforts, we hope to identify a potential new medicine to treat those who are genetically susceptible to certain diseases and associated morbidities.”

“As an academic pharmacologist, it is truly rewarding to see more than a decade’s work lead to a fascinating collaboration with MRC Technology and to this agreement with Pfizer. This is truly within the translational spirit of the research conducted at QMUL,” added Professor Perretti.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Drug Royalties Monetised
MRC Technology monetises royalties on cancer drug Keytruda (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital.
Monday, July 18, 2016
MRC Technology, AstraZeneca Collaborate
Companies launching an initiative to find new epigenetic drug targets in respiratory disease.
Thursday, June 16, 2016
MRC Technology and DEBRA Austria Sign Agreement
MRC Technology, a medical research charity, has signed an agreement to review DEBRA Austria’s research portfolio, aiming to identify promising projects and results which could be suitable for translation into better treatments.
Wednesday, April 27, 2016
MRC Technology Completes Move to Stevenage Open Innovation Campus
Relocation forms part of strategy to foster new collaborative partnerships.
Wednesday, April 20, 2016
MRC Technology and IPS-CAS Collaborate
Company has announced collaboration with Institut Pasteur of Shanghai, Chinese Academy of Sciences to develop new therapeutic antibodies.
Thursday, April 07, 2016
MRC Technology Appoints Two New Members to Board of Trustees
MRC Technology, an independent life science medical research charity, has appointed Dr Les Hughes and Dr Mike Romanos to the board of trustees, with effect from 1 March 2016.
Thursday, April 07, 2016
Charity Seeks Diagnostic Partners to Deliver New Patient Treatments
Call for Diagnostics from MRCT for scientists with promising results lead to new tests.
Thursday, October 29, 2015
MRC Technology Appoints Technology Transfer Director
Appointment of Andrew Farquharson as Director from 1 September.
Wednesday, July 08, 2015
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
MRC Technology Appoints Finance Director
MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014.
Friday, April 17, 2015
MRC Technology Negotiates Licence Deal with Quantifoil Micro Tools GmbH for Ultrastable Gold Support (UltrAuFoil) Technology
The gold supports enable the determination of currently intractable protein structures by electron cryomicroscopy.
Tuesday, March 31, 2015
First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!